Pharmacological aspect in treating Tourette syndrome

A tétel rövid nézete
dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.contributor.authorFish, Sharon
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentDrimba, László
dc.contributor.opponentSzentmiklósi, József András
dc.contributor.opponentdeptKenézy Kórház Aneszteziológiai és Intenziv Therápiás Osztályhu_HU
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.date.accessioned2017-08-03T07:56:31Z
dc.date.available2017-08-03T07:56:31Z
dc.date.created2017-04-28
dc.description.abstractTourette's syndrome is a developmental neuropsychiatric disorder characterized by multiple, brief, recurrent, nonrhythmic movements and one or more vocalizations called tics. Management of TS includes: pharmacological agents, behavioral therapy, psychoeducation and deep brain stimulation. The evidence for efficacy of the pharmacological agents used in treatment of TS is often based on open studies or randomized, double-blind, placebo-controlled studies with quite small sample sizes. Hence, there exists only one drug which has been approved for TS widely in Europe, which is haloperidol. However, because of its adverse reactions it is nowadays usually a drug of third line in clinical practice.hu_HU
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent39hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/242842
dc.language.isoenhu_HU
dc.subjectTourette syndromehu_HU
dc.subject.dspaceDEENK Témalista::Orvostudomány::Farmakológiahu_HU
dc.titlePharmacological aspect in treating Tourette syndromehu_HU
Fájlok
Gyűjtemények
Theses (Faculty of Medicine)